1213P Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in a real-life setting (CLEAR)

Abstract

Liquid biopsies have been shown to be reliable as a complementary tool to demonstrate tumor relation mutations. High procedure cost and sub-optimal sensitivity have been hurdles to public funding of this technique in Canadian centers. The CLEAR trial was designed to evaluate the clinical and economic impact of early diagnosis with circulating fragments of DNA (cfDNA) EGFR testing for suspected lung cancer patients. The objectives are to demonstrate clinically relevant improved time to detection of an EGFR mutation, evaluate the impact of cfDNA diagnosis on patient investigation and time to initiate specific EGFR inhibitor therapy.